Prevalence of DAO (diamino Oxidase) Deficiency in Newborns
Launched by AB BIOTEK · Nov 26, 2024
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
Diamine oxidase (DAO) is an enzyme encoded by the AOC1 gene responsible for the degradation of extracellular histamine. There are different factors that can induce a decrease in the DAO activity, with genetic origin being the main one. Currently, multiple genes have been identified SNPs that can alter the correct functioning of the DAO. The four most relevant SNPs that lead to a reduction in the enzymatic activity of DAO or a transcriptional activity decreased in this are the following: c.47C\>T (rs10156191), c.995C\>T (rs1049742), c.1990C\>G (rs1049793) and c.-691G\>T (rs2052129). Clinical...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Newborns
- • Both sexes
- • Explicit acceptance of the parents or guardians of participation through the signature of the informed consent
- Exclusion Criteria:
- • None
About Ab Biotek
AB Biotek is a leading biotechnology company specializing in the development and commercialization of innovative bioprocessing solutions for the fermentation and brewing industries. With a strong commitment to advancing microbial technology, AB Biotek leverages cutting-edge research and development to enhance product quality and efficiency for its clients. The company focuses on delivering tailored solutions that optimize yeast performance and fermentation processes, thereby supporting sustainable practices and driving growth in the beverage sector. Through collaborative partnerships and a robust pipeline of clinical trials, AB Biotek aims to set new standards in biotechnological applications and improve overall industry standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sant Cugat Del Vallès, Barcelona, Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported